Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis | Diabetes | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.  J Clin Invest. 2006;116(7):1784-179216823476PubMedGoogle ScholarCrossref
Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance.  Mol Med. 2008;14(11-12):741-75119009016PubMedGoogle ScholarCrossref
Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.  Eur Heart J. 2008;29(24):2959-297118775919PubMedGoogle ScholarCrossref
Bruun JM, Lihn AS, Verdich C,  et al.  Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans.  Am J Physiol Endocrinol Metab. 2003;285(3):E527-E53312736161PubMedGoogle Scholar
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.  Nature. 2001;414(6865):782-78711742409PubMedGoogle ScholarCrossref
Stroup DF, Berlin JA, Morton SC,  et al; Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group.  Meta-analysis of observational studies in epidemiology: a proposal for reporting.  JAMA. 2000;283(15):2008-201210789670PubMedGoogle ScholarCrossref
Fumeron F, Aubert R, Siddiq A,  et al; Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group.  Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study.  Diabetes. 2004;53(4):1150-115715047634PubMedGoogle ScholarCrossref
Schwarz PE, Towers GW, Fischer S,  et al.  Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter.  Diabetes Care. 2006;29(7):1645-165016801592PubMedGoogle ScholarCrossref
Jalovaara K, Santaniemi M, Timonen M,  et al.  Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population.  Metabolism. 2008;57(8):1130-113418640392PubMedGoogle ScholarCrossref
Vendramini MF, Ferreira SRG, Gimeno SGA, Kasamatsu TS, Miranda WL, Moisés RS.Japanese-Brazilians Diabetes Study Group.  Plasma adiponectin levels and incident glucose intolerance in Japanese-Brazilians: a seven-year follow-up study.  Diabetes Res Clin Pract. 2006;73(3):304-30916546285PubMedGoogle ScholarCrossref
Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians.  Diabetes Care. 2003;26(12):3226-322914633806PubMedGoogle ScholarCrossref
Lindsay RS, Funahashi T, Hanson RL,  et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population.  Lancet. 2002;360(9326):57-5812114044PubMedGoogle ScholarCrossref
Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data.  Epidemiology. 1993;4(3):218-2288512986PubMedGoogle ScholarCrossref
Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis.  Am J Epidemiol. 1992;135(11):1301-13091626547PubMedGoogle Scholar
Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data.  Stata J. 2006;6:40-57Google Scholar
Spranger J, Kroke A, Möhlig M,  et al.  Adiponectin and protection against type 2 diabetes mellitus.  Lancet. 2003;361(9353):226-22812547549PubMedGoogle ScholarCrossref
Daimon M, Oizumi T, Saitoh T,  et al; Funagata study.  Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study.  Diabetes Care. 2003;26(7):2015-202012832305PubMedGoogle ScholarCrossref
Choi KM, Lee J, Lee KW,  et al.  Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans.  Clin Endocrinol (Oxf). 2004;61(1):75-8015212647PubMedGoogle ScholarCrossref
Duncan BB, Schmidt MI, Pankow JS,  et al.  Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study.  Diabetes. 2004;53(9):2473-247815331562PubMedGoogle ScholarCrossref
Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany.  J Am Coll Cardiol. 2006;48(7):1369-137717010797PubMedGoogle ScholarCrossref
Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans.  J Clin Endocrinol Metab. 2006;91(10):3873-387716882743PubMedGoogle ScholarCrossref
Snijder MB, Heine RJ, Seidell JC,  et al.  Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study.  Diabetes Care. 2006;29(11):2498-250317065691PubMedGoogle ScholarCrossref
Wannamethee SG, Lowe GDO, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men.  Diabetes Care. 2007;30(5):1200-120517322479PubMedGoogle ScholarCrossref
Heidemann C, Sun Q, van Dam RM,  et al.  Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women.  Ann Intern Med. 2008;149(5):307-31618765700PubMedGoogle ScholarCrossref
Kanaya AM, Wassel Fyr C, Vittinghoff E,  et al.  Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.  Arch Intern Med. 2006;166(3):350-35616476877PubMedGoogle ScholarCrossref
Ley SH, Harris SB, Connelly PW,  et al.  Adipokines and incident type 2 diabetes in an Aboriginal Canadian population: the Sandy Lake Health and Diabetes Project.  Diabetes Care. 2008;31(7):1410-141518339973PubMedGoogle ScholarCrossref
Mather KJ, Funahashi T, Matsuzawa Y,  et al; Diabetes Prevention Program.  Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.  Diabetes. 2008;57(4):980-98618192541PubMedGoogle ScholarCrossref
Tabák AG, Brunner EJ, Miller MA,  et al.  Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II Study [published online ahead of print April 15, 2009].  Horm Metab Res. 2009;19370507PubMedGoogle Scholar
DerSimonian R, Laird N. Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177-1883802833PubMedGoogle ScholarCrossref
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;21(11):1539-155812111919PubMedGoogle ScholarCrossref
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  Biometrics. 1994;50(4):1088-11017786990PubMedGoogle ScholarCrossref
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.  BMJ. 1997;315(7109):629-6349310563PubMedGoogle ScholarCrossref
Hotta K, Funahashi T, Bodkin NL,  et al.  Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys.  Diabetes. 2001;50(5):1126-113311334417PubMedGoogle ScholarCrossref
Weyer C, Funahashi T, Tanaka S,  et al.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;86(5):1930-193511344187PubMedGoogle ScholarCrossref
Tschritter O, Fritsche A, Thamer C,  et al.  Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.  Diabetes. 2003;52(2):239-24312540592PubMedGoogle ScholarCrossref
Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease.  Diabetes. 2007;56(5):1198-120917303804PubMedGoogle ScholarCrossref
Hivert MF, Manning AK, McAteer JB,  et al.  Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study.  Diabetes. 2008;57(12):3353-335918776141PubMedGoogle ScholarCrossref
Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures?  BMJ. 2005;330(7499):1076-107915879400PubMedGoogle ScholarCrossref
Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?  Diabetologia. 2008;51(6):926-94018392804PubMedGoogle ScholarCrossref
Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.  Metab Syndr Relat Disord. 2008;6(2):87-10218510434PubMedGoogle ScholarCrossref
Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study.  Am J Clin Nutr. 2008;88(5):1213-122418996855PubMedGoogle Scholar
Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve.  Clin Chem. 2008;54(1):17-2318024533PubMedGoogle ScholarCrossref
Clinical Review
Clinician's Corner
July 8, 2009

Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis

Author Affiliations

Author Affiliations: Departments of Epidemiology (Drs Li and van Dam) and Nutrition (Drs Shin, Ding, and van Dam), Harvard School of Public Health, Boston, Massachusetts; Framingham Union Hospital Metro West Medical Center, Framingham, Massachusetts (Dr Shin); and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (Dr van Dam).

JAMA. 2009;302(2):179-188. doi:10.1001/jama.2009.976

Context The association of obesity with development of type 2 diabetes may be partly mediated by altered secretion of adipokines by adipose tissue. Greater adiposity down-regulates secretion of adiponectin, an adipokine with anti-inflammatory and insulin-sensitizing properties. The strength and consistency of the relation between plasma adiponectin and risk of type 2 diabetes is unclear.

Objective To systematically review prospective studies of the association of plasma adiponectin levels and risk of type 2 diabetes.

Data Sources A systematic search of the MEDLINE, EMBASE, and Science Citation Index Expanded databases using adiponectin and diabetes and various synonyms and reference lists of retrieved articles up to April 10, 2009.

Study Selection We included prospective studies with plasma adiponectin levels as the exposure and incidence of type 2 diabetes as the outcome variable.

Data Extraction Two reviewers independently extracted data and assessed study quality. Generalized least-squares trend estimation was used to assess dose-response relationships. Pooled relative risks and 95% confidence intervals were calculated using random-effects models to incorporate between-study variation.

Results Thirteen prospective studies with a total of 14 598 participants and 2623 incident cases of type 2 diabetes were included in the meta-analysis. Higher adiponectin levels were monotonically associated with a lower risk of type 2 diabetes. The relative risk of type 2 diabetes was 0.72 (95% confidence interval, 0.67-0.78) per 1–log μg/mL increment in adiponectin levels. This inverse association was consistently observed in whites, East Asians, Asian Indians, African Americans, and Native Americans and did not differ by adiponectin assay, method of diabetes ascertainment, duration of follow-up, or proportion of women. The estimated absolute risk difference (cases per 1000 person-years) per 1–log μg/mL increment in adiponectin levels was 3.9 for elderly Americans and 30.8 for Americans with impaired glucose tolerance.

Conclusion Higher adiponectin levels are associated with a lower risk of type 2 diabetes across diverse populations, consistent with a dose-response relationship.